https://www.kaziatx.com/investors/news-and-events/press-releases/rss en-us https://s3.amazonaws.com/equisolve-dev4/kaziatherapeutics/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite https://www.kaziatx.com/investors/news-and-events/press-releases/detail/223/kazia-therapeutics-announces-first-patient-dosed-in-pnoc035-clinical-study-evaluating-paxalisib-for-recurrent-pediatric-atrt-brain-cancer Wed, 09 Sep 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/223/kazia-therapeutics-announces-first-patient-dosed-in-pnoc035-clinical-study-evaluating-paxalisib-for-recurrent-pediatric-atrt-brain-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/222/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy Tue, 01 Sep 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/222/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy https://www.kaziatx.com/investors/news-and-events/press-releases/detail/221/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hr-her2--breast-cancer-supported-by-preclinical-data-showing-strong-clinical-activity-and-safety-in-hr-breast-cancer Tue, 01 Sep 26 07:15:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/221/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hr-her2--breast-cancer-supported-by-preclinical-data-showing-strong-clinical-activity-and-safety-in-hr-breast-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/220/kazia-therapeutics-limited-announces-oversubscribed-closing-of-up-to-120-million-public-offering Mon, 31 Aug 26 17:58:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/220/kazia-therapeutics-limited-announces-oversubscribed-closing-of-up-to-120-million-public-offering https://www.kaziatx.com/investors/news-and-events/press-releases/detail/218/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-public-offering Fri, 28 Aug 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/218/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-public-offering https://www.kaziatx.com/investors/news-and-events/press-releases/detail/217/kazia-therapeutics-limited-announces-proposed-public-offering Thu, 27 Aug 26 16:09:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/217/kazia-therapeutics-limited-announces-proposed-public-offering https://www.kaziatx.com/investors/news-and-events/press-releases/detail/216/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer Thu, 27 Aug 26 16:01:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/216/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/219/kazia-therapeutics-announces-the-filing-of-provisional-patent-for-novel-strategy-supported-by-preclinical-data-to-prevent-metastatic-recurrence-in-triple-negative-breast-cancer Tue, 28 Jul 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/219/kazia-therapeutics-announces-the-filing-of-provisional-patent-for-novel-strategy-supported-by-preclinical-data-to-prevent-metastatic-recurrence-in-triple-negative-breast-cancer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/215/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer Tue, 02 Jun 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/215/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer https://www.kaziatx.com/investors/news-and-events/press-releases/detail/214/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer Tue, 26 May 26 07:30:00 -0400 https://www.kaziatx.com/investors/news-and-events/press-releases/detail/214/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer